Riahi Sam, Schmidt Erik Berg, Christensen Jeppe Hagstrup, Heath Finn, Pedersen Anders Kirstein, Nielsen Jens Cosedis, Mølgaard Henning, Toft Egon
Department of Cardiology, Cardiovascular Research Center, Aalborg Hospital, Arhus University, Aalborg, Denmark.
Cardiology. 2005;104(4):210-4. doi: 10.1159/000088175. Epub 2005 Sep 9.
The aim of this study was to evaluate whether the incidence of ventricular arrhythmias and heart rate variability were influenced by statin treatment and lipid levels in patients treated with an implantable cardioverter defibrillator (ICD). Heart rate variability measurements were performed in 86 patients with coronary heart disease and an ICD implant. The number of events with ventricular fibrillation and ventricular tachycardia were recorded during a 12-month period. This study lends little support for an antiarrhythmic effect of statins or any relation between plasma lipids and lipoproteins and malignant ventricular arrhythmias in patients with an ICD.
本研究的目的是评估在植入式心脏复律除颤器（ICD）治疗的患者中，他汀类药物治疗和血脂水平是否会影响室性心律失常的发生率和心率变异性。对86例植入ICD的冠心病患者进行了心率变异性测量。记录了12个月期间室颤和室性心动过速的事件数量。本研究几乎没有支持他汀类药物的抗心律失常作用，或血浆脂质和脂蛋白与ICD患者恶性室性心律失常之间存在任何关联。
